Matthew Wongchenko

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

Paolo A. Ascierto, Grant A. McArthur, Brigitte Dréno et al. · The Lancet Oncology · 2016 · 986 citations

Medicine, Advanced Brafv600-mutant Melanoma, Melanoma +7

Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy

Tuba N. Gide, Camelia Quek, Alexander M. Menzies et al. · Cancer Cell · 2019 · 980 citations · Full text

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

Jennifer L. McQuade, Carrie R. Daniel, Kenneth R. Hess et al. · The Lancet Oncology · 2018 · 647 citations · Full text

Oncology, Body Composition, Cancer Management +8

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Sung‐Bae Kim, Rebecca Dent, Seock‐Ah Im et al. · The Lancet Oncology · 2017 · 463 citations · Full text

First-line Therapy, Breast Oncology, Medicine +7

An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells

Maia Vinogradova, Victor Gehling, Amy Gustafson et al. · Nature Chemical Biology · 2016 · 343 citations · Full text

Drug-tolerant Cancer Cells, Medicine, Anti-cancer Agent +7